Target Information
Target General Infomation | |||||
---|---|---|---|---|---|
Target ID |
T34624
|
||||
Former ID |
TTDR00365
|
||||
Target Name |
Stress kinase p38
|
||||
Synonyms |
MAP kinase p38; Mitogen-activated protein kinase p38; P38 MAP kinase; P38 MAPK; Stress-activated protein kinase
|
||||
Target Type |
Clinical Trial
|
||||
Disease | Asthma [ICD10: J45] | ||||
Atherosclerosis; Psoriasis [ICD9:414.0, 440, 696; ICD10: I70, L40] | |||||
Chronic obstructive pulmonary disease; Asthma [ICD9: 490-492, 493, 494-496; ICD10: J40-J44, J47, J45] | |||||
Chronic obstructive pulmonary disease [ICD9: 490-492, 494-496; ICD10: J40-J44, J47] | |||||
Cancer [ICD9: 140-229; ICD10: C00-C96] | |||||
Inflammatory disease [ICD9: 140-229, 147, 173, 573.3, 710-719; ICD10: C11, C44, K75.9, M00-M25] | |||||
Rheumatoid arthritis [ICD9: 710-719, 714; ICD10: M05-M06] | |||||
BioChemical Class |
Kinase
|
||||
EC Number |
EC 2.7.1.37
|
||||
Drugs and Mode of Action | |||||
Drug(s) | AZD7624 | Drug Info | Phase 2 | Chronic obstructive pulmonary disease | [524912] |
BMS-582949 | Drug Info | Phase 2 | Atherosclerosis; Psoriasis | [522211], [542780] | |
GSK2269557 | Drug Info | Phase 2 | Chronic obstructive pulmonary disease; Asthma | [525290] | |
TAK-715 | Drug Info | Phase 2 | Rheumatoid arthritis | [522447] | |
LY-2228820 | Drug Info | Phase 1/2 | Cancer | [524019], [542875] | |
AVE-9940 | Drug Info | Discontinued in Phase 1 | Rheumatoid arthritis | [548220] | |
AZD-6703 | Drug Info | Discontinued in Phase 1 | Rheumatoid arthritis | [542667], [548025] | |
SB-281832 | Drug Info | Discontinued in Phase 1 | Asthma | [547451] | |
TA-5493 | Drug Info | Discontinued in Phase 1 | Inflammatory disease | [548178] | |
AMG-548 | Drug Info | Terminated | Inflammatory disease | [547846] | |
References | |||||
Ref 522211 | ClinicalTrials.gov (NCT00605735) PoC in Rheumatoid Arthritis With Methotrexate. U.S. National Institutes of Health. | ||||
Ref 522447 | ClinicalTrials.gov (NCT00760864) Safety and Efficacy of TAK-715 in Subjects With Rheumatoid Arthritis. U.S. National Institutes of Health. | ||||
Ref 524019 | ClinicalTrials.gov (NCT01663857) A Study of LY2228820 for Recurrent Ovarian Cancer. U.S. National Institutes of Health. | ||||
Ref 524912 | ClinicalTrials.gov (NCT02238483) A Phase IIa Study to Investigate the Efficacy and Safety of AZD7624 in Chronic Obstructive Pulmonary Disease (COPD) Patients While on Maintenance Therapy. U.S. National Institutes of Health. | ||||
Ref 525290 | ClinicalTrials.gov (NCT02522299) A Study to Evaluate the Safety, Efficacy and Changes in Induced Sputum and Blood Biomarkers Following Daily Repeat Doses of Inhaled GSK2269557 in Chronic Obstructive Pulmonary Disease (COPD) Subjects With Acute Exacerbation. | ||||
Ref 542667 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7687). | ||||
Ref 542780 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7838). | ||||
Ref 542875 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7959). | ||||
Ref 547451 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800016500) | ||||
Ref 547846 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019881) | ||||
Ref 548025 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021256) | ||||
Ref 526851 | p38 MAPK inhibitors ameliorate target organ damage in hypertension: Part 1. p38 MAPK-dependent endothelial dysfunction and hypertension. J Pharmacol Exp Ther. 2003 Dec;307(3):932-8. Epub 2003 Oct 15. | ||||
Ref 527639 | p38 MAP kinase inhibitors: many are made, but few are chosen. Curr Opin Drug Discov Devel. 2005 Jul;8(4):421-30. | ||||
Ref 531443 | Inhibition of Wnt/beta-catenin signaling by p38 MAP kinase inhibitors is explained by cross-reactivity with casein kinase Idelta/?. Chem Biol. 2011 Apr 22;18(4):485-94. | ||||
Ref 531914 | The discovery of N-cyclopropyl-4-methyl-3-[6-(4-methylpiperazin-1-yl)-4-oxoquinazolin-3(4H)-yl]benzamide (AZD6703), a clinical p38alpha MAP kinase inhibitor for the treatment of inflammatory diseases. Bioorg Med Chem Lett. 2012 Jun 15;22(12):3879-83. | ||||
Ref 531958 | Evaluation of WO2012032067 and WO2012055846: two selective PI3Kdelta inhibitors, which is GSK-2269557. Expert Opin Ther Pat. 2012 Aug;22(8):965-70. | ||||
Ref 532303 | Synthesis and evaluation of carbamoylmethylene linked prodrugs of BMS-582949, a clinical p38alpha inhibitor. Bioorg Med Chem Lett. 2013 May 15;23(10):3028-33. | ||||
Ref 533111 | Investigational p38 inhibitors for the treatment of chronic obstructive pulmonary disease. Expert Opin Investig Drugs. 2015 Mar;24(3):383-92. | ||||
Ref 542875 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7959). |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.